Tags
Blog

'neurology' posts

What is ALS and why did it inspire ice bucket challenges at Swedish?

Employees of Swedish Cherry Hill Outpatient Rehabilitation and Neurology Departments took the plunge and participated in the ALS Ice Bucket Challenge to raise awareness of ALS and funding for ALS research.  (Click here to see their video on Facebook.)




Before the ALS clinic team takes the ice bucket challenge
 
Amyotrophic Lateral Sclerosis (ALS), most commonly referred to as “Lou Gehrig’s Disease”, is a progressive neurodegenerative disease which affects the motor neurons responsible for voluntary movements and muscle power. As the disease progresses, individuals living with ALS may lose their ability to move and control the muscles of their extremities, torso, head and mouth which can make completion of basic activities such as walking, eating, talking and even breathing very difficult.

Unfortunately, the disease has no cure and only one medication has been approved for the treatment of ALS. Research is making strides towards understanding the underlying physiology and genetic makeup of the disease. Because of  ...

Ketogenic diet as a treatment for seizures

The ketogenic diet is a high-fat, low-carbohydrate diet that has proven to be effective in the treatment of seizures. In fact, the ketogenic diet is one of the oldest and most effective treatments available for patients with seizures regardless of age, from infancy through adulthood. The ketogenic diet must only be started under direct medical supervision.

Here are some frequently asked questions about the ketogenic diet:

What is the ketogenic diet?
The ketogenic diet is a special high-fat diet that often includes heavy cream, butter and vegetable oils to provide the necessary fat. The diet eliminates carbohydrate rich foods such as bread, rice, cereals, pasta, cookies, and cakes.

How effective is the diet at controlling or eliminating seizures?
Studies that have followed children on the diet for long periods reveal that at least 2/3 of all children on the diet have a significant reduction in seizures by over half. 1/3 of children on the diet will have a greater than 90% reduction in seizures, with half of these children ....

Do you know the symptoms of a brain aneurysm?

It’s easy to get caught up in day-to-day demands and ignore changes in our health. It may not be wise, however, to dismiss those changes as symptoms of a hectic life. Blurred vision, dizziness or headaches that don’t get better can signal something serious.

Anywhere from 1 to 6 percent of Americans have a brain aneurysm but don’t know it. An aneurysm is a blister-like bulge on the wall of a blood vessel. It can go unnoticed for a long time. If it’s not treated, the pressure of the blood weakens the vessel, and the aneurysm grows like a balloon filling with air. If the aneurysm bursts, it causes a stroke.

An aneurysm can put pressure on nerves or tissue in the brain, which may cause:

  • Headache or neck pain
  • Vision problems, enlarged pupil, drooping eye lid
  • Numb face
  • Severe drowsiness

If you have a brain aneurysm, your doctor may ...

Swedish Offers New Treatment for Glioblastoma Brain Tumors

SEATTLE, Feb. 6, 2013 – Swedish Neuroscience Institute has added a new and innovative therapy to its treatment arsenal for glioblastoma multiforme (GBM) – a very aggressive and difficult to control brain tumor.

Swedish Set to Open State-of-the-Art Multiple Sclerosis Center; New Facility Has Been Under Development for Several Years and Largely Funded Through Philanthropy

SEATTLE – April 6, 2012 – Swedish Neuroscience Institute (SNI) is set to open its new MS Center to patients. Carefully designed for easy accessibility and to promote the well-being of people with MS, the new 11,700-square-foot center gives SNI the ability to consolidate all of its MS services into one facility. An additional 1,500-square-feet of outside therapy terrace will provide a safe environment for patients to work with a therapist on improving their gait over different terrain.

The new center also enables scientists, researchers, physicians and patients to work collaboratively toward new treatment options for those diagnosed with MS. In a move that further establishes Swedish’s neuroscience program as a leader in the region, the MS Center at Swedish is the largest, most comprehensive facility of its kind on the West Coast and one of only a handful in the country.

The Spring Issue of BrainWaves Is Now Available

The Spring 2011 edition of BrainWaves is now available online.

BrainWaves is the newsletter of the Swedish Neuroscience Institute. Published quarterly, BrainWaves provides information about neurological conditions treated at the Institute, and also profiles the programs, services, and new initiatives of the institute and its staff.

Also check out our past editions of the BrainWaves newsletter.

Advances in thrombolysis

 Washington State has one of the high est stroke mortality rates in the nation. To improve this situation, acute intervention al therapies for stroke are being employed to restore circulation to ischemic brain tissue that surrounds areas of completed infraction, while avoiding risk of hemor rhage due to reperfusion of large areas of infracted brain tissue.

Urgent thrombolysis with intrave nous alteplase is the only therapy known to improve clinical outcomes following acute stroke. Unfortunately, alteplase has had limited usage because many patients arrive in an emergency department after the three-hour treatment window. The FDA has also approved two clot removal devices based on the ability to restore circulation. These devices are used up to eight hours after symptom onset. Several approaches to improved acute stroke care are now under way, including extension of the thrombolysis window to 4.5 hours, identification of safer thrombolytic agents and research identifying brain at risk of in farction following a stroke.

A recent European study demonstrat ed the efficacy of alteplase up to 4.5 hours after ischemic stroke in patients younger than age 80 years who have neither dia betes mellitus or prior stroke. The safety profile during this longer window for these patients appears similar to that at three hours.

Another promising advance employs a new thrombolytic agent called des moteplase.

Results 1-7 of 17